Albireo Pharma, Inc. (NASDAQ:ALBO)‘s stock had its “buy” rating restated by analysts at Cowen and Company in a note issued to investors on Friday.

The analysts wrote, “Albireo reported 3Q earnings today and provided a brief summary of recent progress.””

Several other research firms also recently weighed in on ALBO. Zacks Investment Research downgraded shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 13th. Needham & Company LLC restated a “buy” rating on shares of Albireo Pharma in a research report on Thursday, October 26th. Roth Capital began coverage on shares of Albireo Pharma in a research report on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of Albireo Pharma in a research report on Monday, September 11th. Finally, ValuEngine lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $53.75.

Albireo Pharma (NASDAQ:ALBO) traded up $0.42 during midday trading on Friday, reaching $25.99. 15,800 shares of the company were exchanged, compared to its average volume of 23,793. Albireo Pharma has a 1-year low of $15.31 and a 1-year high of $37.69.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings data on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). analysts forecast that Albireo Pharma will post -3.6 EPS for the current fiscal year.

WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/18/biodel-inc-albo-given-buy-rating-at-cowen-and-company.html.

An institutional investor recently raised its position in Albireo Pharma stock. Renaissance Technologies LLC increased its position in Albireo Pharma, Inc. (NASDAQ:ALBO) by 0.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Albireo Pharma were worth $3,591,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 27.29% of the company’s stock.

Albireo Pharma Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.